Table 2.

Risks of hypertension with abiraterone

	MOA	Incidence (95% CI)	Relative risk (95% CI)	References
abiraterone and prednisone	Androgen biosynthesis (CYP-17 inhibitor)	21.9% (13.6–33.2%)	1.80 (1.47–2.19)	This study
enzalutamide [26]	Anti-Androgen receptor	14%	3.41	Package insert a
leuprolide [34]	Androgen biosynthesis (LHRH analogs)	6.6%	NA	Package insert
firmagon [35]	Androgen biosynthesis (LHRH antagonist)	7%	NA	Package insert

Abbreviations: MOA mechanism of action, LHRH luteinizing hormone releasing hormone. ^aThe incidence and RR were calculated from PREVAIL trial